How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,006 results for

Subcutaneous Fat Necrosis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

941. Assessment and Management of Stage I to IV Pressure Ulcers

visible blanching; its colour may differ from the surrounding area. Nursing Best Practice GuidelineAssessment & Management of Stage I to IV Pressure Ulcers 22 Stage II: Partial thickness loss of dermis presenting as a shallow open ulcer with a red pink wound bed, without slough. May also present as an intact or open/ruptured serum-filled blister. Stage III: Full thickness tissue loss. Subcutaneous fat may be visible but bone, tendon or muscle are not exposed. Slough may be present but does not obscure

2002 Registered Nurses' Association of Ontario

943. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. (PubMed)

subjects matched for age, height, weight, and physical activity to assess the sensitivity of liver and muscle to insulin. Proton ((1)H) magnetic resonance spectroscopy studies were performed to measure intramyocellular lipid and intrahepatic triglyceride content. Rates of whole-body and subcutaneous fat lipolysis were assessed by measuring the rates of [(2)H(5)]glycerol turnover in combination with microdialysis measurements of glycerol release from subcutaneous fat. We performed (31)P magnetic (...) dysfunction, as reflected by a reduction of approximately 30 percent in mitochondrial phosphorylation (P=0.01 for the comparison with controls), since there were no significant differences in systemic or localized rates of lipolysis or plasma concentrations of tumor necrosis factor alpha, interleukin-6, resistin, or adiponectin.These data support the hypothesis that insulin resistance in the skeletal muscle of insulin-resistant offspring of patients with type 2 diabetes is associated with dysregulation

Full Text available with Trip Pro

2004 NEJM

944. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. (PubMed)

infusions) as well as levels of inflammatory mediators and other risk factors for coronary heart disease in 15 obese women before and 10 to 12 weeks after abdominal liposuction. Eight of the women had normal glucose tolerance (mean [+/-SD] body-mass index, 35.1+/-2.4), and seven had type 2 diabetes (body-mass index, 39.9+/-5.6).Liposuction decreased the volume of subcutaneous abdominal adipose tissue by 44 percent in the subjects with normal glucose tolerance and 28 percent in those with diabetes; those (...) with normal oral glucose tolerance lost 9.1+/-3.7 kg of fat (18+/-3 percent decrease in total fat, P=0.002), and those with type 2 diabetes lost 10.5+/-3.3 kg of fat (19+/-2 percent decrease in total fat, P<0.001). Liposuction did not significantly alter the insulin sensitivity of muscle, liver, or adipose tissue (assessed by the stimulation of glucose disposal, the suppression of glucose production, and the suppression of lipolysis, respectively); did not significantly alter plasma concentrations of C

2004 NEJM

945. What is the effect of liposuction on CHD risk factors in overweight and/or obese patients?

obese women before and 10 to 12 weeks after abdominal liposuction. Eight of the women had normal glucose tolerance (mean [+/-SD] body-mass index, 35.1+/-2.4), and seven had type 2 diabetes (body-mass index, 39.9+/-5.6). RESULTS: Liposuction decreased the volume of subcutaneous abdominal adipose tissue by 44 percent in the subjects with normal glucose tolerance and 28 percent in those with diabetes; those with normal oral glucose tolerance lost 9.1+/-3.7 kg of fat (18+/-3 percent decrease in total (...) fat, P=0.002), and those with type 2 diabetes lost 10.5+/-3.3 kg of fat (19+/-2 percent decrease in total fat, P Liposuction did not significantly alter the insulin sensitivity of muscle, liver, or adipose tissue (assessed by the stimulation of glucose disposal, the suppression of glucose production, and the suppression of lipolysis, respectively); did not significantly alter plasma concentrations of C-reactive protein, interleukin-6, tumor necrosis factor alpha, and adiponectin; and did

2006 TRIP Answers

946. Crixivan - indinavir

not associated with drug-induced renal injury. In rats administered very high doses of indinavir, renal tubular necrosis and vacuolation were observed. Serum biochemical, haematological and urinanalytical changes were noted in rats and mice exposed to indinavir concentrations in the clinical range. These changes seem to be of minor toxicological significance. Repeated dose toxicity studies in rats and dogs given indinavir sulphate at doses up to 160 mg/kg/day together with two degradates did not show any (...) studies. Data from 374 subjects was presented, of whom 179 were HIV patients. The vast majority of the subjects included were male (84 %). One study was performed in subjects with mild to moderate hepatic impairment. Indinavir is rapidly absorbed in the fasted state (T max of 0.8 hours) with an absolute bioavailability of approximately 60 % within the dose range of 400 mg to 800 mg. The bioavailability of a single 800 mg dose was approximately 65 %. Administration of a 400 mg dose with a high-fat

2005 European Medicines Agency - EPARs

947. Beromun (tasonermin)

Beromun (tasonermin) CPMP/2/99 1/23 EMEA 2000 SCIENTIFIC DISCUSSION Name of the medicinal product: Beromun Marketing Authorisation Holder: Boehringer Ingelheim International GmbH Binger Strasse 173 D-55216 Ingelheim am Rhein Germany Active substance: Tumor necrosis factor alfa-1a International Nonproprietary Name: Tasonermin Pharmaco-therapeutic group (ATC Code): LO3AA Therapeutic indication: As an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation (...) , or in the palliative situation, for irresectable soft tissue sarcoma of the limbs, used in combination with melphalan via mild hyperthermic isolated limb perfusion (ILP).CPMP/2/99 2/23 EMEA 2000 1. Introduction Beromun contains the active ingredient tasonermin also known as tumour necrosis factor alfa-1a or TNFa-1a. Tasonermin is a non-glycosylated cytokine produced from E.coli using rDNA technology. The protein consists of three identical polypeptide chains of 157 amino acids combined to form a compact, bell

2005 European Medicines Agency - EPARs

948. Aloxi (palonosetron hydrochloride)

apparent in lungs, liver, adrenals and testes and lowest in fat, bone (without marrow) and the medulla (brain). Concentrations generally peaked within two hours, later peaks were observed in skin, testes, liver, stomach, bone and fat. Concentration ratios in the brain peaked at 30 min; chromatographic analysis indicated only palonosetron, no metabolites. The kinetic pattern in the brain mirrored that in plasma, indicating rapid elimination. By 96 hours, concentrations in all tissues, except the eye (...) weights were reduced in males at 120 mg/kg/day. In a one-month rat study changes at 180 mg/kg/day included reduced body weight gain, occasional signs and numerous clinical pathology variations, most of which were within the normal range. Low testis and secondary sex organ weights were associated with degeneration and necrosis of the seminiferous epithelium. Low thymus weights in females associated with lymphoid depletion and high liver weights in both sexes with foamy cytoplasmic swelling

2006 European Medicines Agency - EPARs

949. Cervarix - human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed)

thereafter following intramuscular administration, and at 168 hours post-dose was 11.4 ng equivalents of MPL/g. The elimination half-life following intravenous administration was 76.5 hours. Relatively low quantifiable levels of radioactivity were detected in all tissues investigated at 56 days post-dose in both studies, with the highest concentrations observed in the fat and spleen. The routes and rates of elimination were similar following both intramuscular and intravenous administration. The major (...) % of the dose appeared to be absorbed. However, the total absorption is likely to be much higher than this value since only 0.2% of the dose was recovered from the injection site. In conclusion the pharmacokinetic studies conducted in rats have shown that MPL-related material is widely distributed throughout the body, notably to the fat and spleen, and is then likely eliminated mainly via the expired air, with only low levels of radioactivity remaining in the carcass. Toxicology • Single dose toxicity

2007 European Medicines Agency - EPARs

950. Radiation Therapy, Cyclophosphamide, and Doxorubicin in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery

atrophy, moderate telangectasias, total hair loss, 3= Marked atrophy, gross telangectasias, 4= Ulceration; Subcutaneous Tissue Toxicity: 0= None, 1= Slight induration (fibrosis) and loss of subcutaneous fat, 2= Moderate fibrosis but asymptomatic; slight field contracture; <10% linear reduction, 3= Severe induration and loss subcutaneous tissue; field contracture >10% linear reduction; 4= Necrosis Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate (...) : Assess the potential acute and late skin and subcutaneous toxicities in women with resected stage I or II breast cancer treated with partial breast irradiation (PBI) and concurrent cyclophosphamide/doxorubicin (AC) chemotherapy. Assess the cosmetic effects of partial breast irradiation/chemotherapy (PBIC) in these patients. Assess the local control rate in patients treated with this regimen. OUTLINE: Patients undergo partial breast radiotherapy once daily, 5 days a week, for 3 weeks. Patients also

2006 Clinical Trials

951. BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

plasma concentration versus time data. AUC (TAU) of Tenofovir at Week 4 [ Time Frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 Hrs post dosing with ATV/RTV and TDF all given QD and at predose, 1, 2, 3, 4, 6, 8, 12 Hrs post dosing with LPV/RTV given BID and TDF given QD. ] AUC (TAU) was derived from plasma concentration versus time data.It was calculated from time 0-24 hours for tenofovir in LPV/RPV and ATV/RTV regimen at Week 4. Mean Change From Baseline in Trunk-to-Limb Fat Ratio as Measured (...) by Dual Energy X-ray Absorptiometry (DEXA) at Week 96 [ Time Frame: Baseline (Day 1) and Week 96. ] Mean changes from baseline in trunk-to-limb fat ratio as measured by DEXA, an x-ray scan used to measure bone mineral density. Clinical improvement is associated with a decrease in values. Number of Participants With Single Nucleotide Polymorphisms (SNPs) Included in Genotype-Phenotype Analysis [ Time Frame: Baseline visit ] 19 genes of interest were selected from previous results or literature, and 34

2006 Clinical Trials

952. Telmisartan-Induced Reduction in Intra-Myocellular Lipids Trial

) Heart and Stroke Foundation of Canada Medtronic Information provided by: McMaster University Study Details Study Description Go to Brief Summary: The purpose of this study is to determine whether telmisartan and/or a low-glycemic index diet are effective in reducing intra-myocellular lipid (muscle fat) content. Condition or disease Intervention/treatment Phase Metabolic Syndrome X Drug: Telmisartan (Micardis®) vs. Placebo Behavioral: Low-Glycemic Index Diet vs. Control Diet Phase 3 Detailed (...) Description: The metabolic syndrome currently affects over 20% of the adult population in Canada. Patients with abdominal obesity are at markedly increased risk for diabetes and heart disease. Recent studies have shown that decreased sensitivity to insulin (insulin resistance), a hallmark of the metabolic syndrome, is related to increased storage of fat in muscle cells (muscle fat). Several recent studies indicate that blocking the renin-angiotensin system (RAS) may improve insulin sensitivity and prevent

2005 Clinical Trials

953. Latino Study

microgram (mcg)/0.5 mL by subcutaneous injection once a week in combination with ribavirin 1000 or 1200 mg per day, which was taken orally in split doses for 48 weeks. Participants with <75 kg (165 lbs) of body weight received 1000 mg/day (400 mg in the morning and 600 mg in the evening). Participants with >=75 kg (165 lbs) of body weight received 1200 mg/day (600 mg in the morning and 600 mg in the evening). Drug: Ribavirin 1000-1200mg po daily for 48 weeks Drug: Peginterferon alfa-2a 180 micrograms sc (...) /week for 48 weeks Experimental: Non-Latino White Participants received peginterferon alfa-2a 180 mcg/0.5 mL by subcutaneous injection once a week in combination with ribavirin 1000 or 1200 mg per day which was taken orally in split doses. Participants with <75 kg (165 lbs) of body weight received 1000 mg/day. Participants with >=75 kg (165 lbs) of body weight received 1200 mg/day for 48 weeks. Drug: Ribavirin 1000-1200mg po daily for 48 weeks Drug: Peginterferon alfa-2a 180 micrograms sc/week

2005 Clinical Trials

954. Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer

Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan [ Time Frame: Within 1 year of protocol registration ] -The study will be deemed infeasible if more than 4 patients cannot be given treatment because her tumor is such that a dosimetrically satisfactory treatment plan cannot be devised for her. Feasibility of PBI Directed External Radiotherapy as Measured by Development of Histological Fat Necrosis or Other Grade 4 Skin or Grade 4 Subcutaneous (...) Toxicity, or Requires Surgery for the Skin/Subcutaneous Toxicity [ Time Frame: Within 1 year of protocol registration ] -The study will be deemed infeasible if more than 4 patients develop histological fat necrosis or other grade 4 skin or grade 4 subcutaneous toxicity, or requires surgery for her skin or subcutaneous toxicity Secondary Outcome Measures : Incidence and Severity of Cutaneous Toxicity [ Time Frame: Up to 5 years ] Uses RTOG/EORTC Late Radiation Morbidity Scoring Scheme Grade 0 = none

2006 Clinical Trials

955. Effects of different hypocaloric diets on protein secretion from adipose tissue of obese women. (PubMed)

-linked immunosorbent assays) from subcutaneous adipose tissue in 40 obese but otherwise healthy women. Similar results were obtained by the two diets. Body weight decreased by approximately 7.5%. The secretion rate of leptin decreased by approximately 40%, as did that of tumor necrosis factor-alpha (TNF-alpha), and interleukin (IL)-6 and -8 decreased by 25-30%, whereas the secretion of plasminogen activator inhibitor 1 (PAI-1) and adiponectin did not show any changes. Regarding mRNA expression (...) Effects of different hypocaloric diets on protein secretion from adipose tissue of obese women. Little is known about common factors (e.g., macronutrients and energy supply) regulating the protein secretory function of adipose tissue. We therefore compared the effects of randomly assigned 10-week hypoenergetic (-600 kcal/day) diets with moderate-fat/moderate-carbohydrate or low-fat/high-carbohydrate content on circulating levels and production of proteins (using radioimmunoassays and enzyme

2004 Diabetes

956. Influence of parturition and diets enriched in n-3 or n-6 polyunsaturated fatty acids on immune response of dairy cows during the transition period. (PubMed)

Influence of parturition and diets enriched in n-3 or n-6 polyunsaturated fatty acids on immune response of dairy cows during the transition period. The objectives of this study were to evaluate the functional properties of immunocompetent cells in dairy cows fed diets enriched in n-3 or n-6 polyunsaturated fatty acids during the transition period. Six weeks before calving, 21 primiparous and 27 multiparous pregnant Holstein dairy cows were randomly allotted to 1 of 3 dietary fat treatments (...) : calcium salts of palm oil (Megalac), micronized soybeans, or whole flaxseed, which are, respectively, rich in saturated, n-6, or n-3 fatty acids. On wk 6 and 3 before parturition, cows received a subcutaneous injection of ovalbumin to measure the antibody response in colostrum and serum. Colostrum samples were collected at the first milking after calving, and blood samples were taken 6, 3, and 1 wk before the expected calving date and 1, 3, and 6 wk after calving. Blood mononuclear cells were cultured

2004 Journal of dairy science

957. Changes in serum levels of E-selectin correlate to improved glycaemic control and reduced obesity in subjects with the metabolic syndrome. (PubMed)

the effect of physical exercise and pravastatin (40 mg daily) on serum levels of CAMs and a possible role of adipose tissue in regulating serum levels of CAMs were investigated.The study was designed as an unmasked randomized 2x2 factorial trial of 12 weeks duration in 32 subjects with the metabolic syndrome. Changes from baseline were studied, and correlations between changes in CAMs, anthropometric measures, regional fat distribution, glycaemic control and the adipocytokine tumour necrosis factor (...) -a (TNF-a) and adiponectin were investigated.No significant changes in CAMs were observed in any of the intervention groups. However, when examining the whole study population regardless of intervention, changes in serum E-selectin were significantly correlated to changes in body mass index (r=0.48, p=0.006), waist circumference (r=0.48, p=0.006), fasting glucose (r=0.43, p=0.02) and HbA1c (r=0.45, p=0.01), but not to changes in visceral fat, subcutaneous fat, TNF-a or adiponectin.Changes in glycaemic

2005 Scandinavian journal of clinical and laboratory investigation

958. Adipocyte death, adipose tissue remodeling, and obesity complications. (PubMed)

Adipocyte death, adipose tissue remodeling, and obesity complications. We sought to determine the role of adipocyte death in obesity-induced adipose tissue (AT) inflammation and obesity complications.Male C57BL/6 mice were fed a high-fat diet for 20 weeks to induce obesity. Every 4 weeks, insulin resistance was assessed by intraperitoneal insulin tolerance tests, and epididymal (eAT) and inguinal subcutaneous AT (iAT) and livers were harvested for histological, immunohistochemical, and gene (...) expression analyses.Frequency of adipocyte death in eAT increased from <0.1% at baseline to 16% at week 12, coincident with increases in 1) depot weight; 2) AT macrophages (ATM Phi s) expressing F4/80 and CD11c; 3) mRNA for tumor necrosis factor (TNF)-alpha, monocyte chemotactic protein (MCP)-1, and interleukin (IL)-10; and 4) insulin resistance. ATM Phi s in crown-like structures surrounding dead adipocytes expressed TNF-alpha and IL-6 proteins. Adipocyte number began to decline at week 12. At week 16

Full Text available with Trip Pro

2007 Diabetes

959. Microvascular alterations in diabetic mice correlate with level of hyperglycemia. (PubMed)

/DTA mice might play a role in impaired wound healing observed in diabetes. The increased permeability in subcutaneous tissue may serve as predictor of vascular changes in early stages of diabetes. The increased LEI and serum tumor necrosis factor-alpha levels, which mirror the inflammatory process, support the growing evidence of the inflammatory component of diabetic disease. The results suggest that anti-inflammatory strategies might be able to prevent vascular deterioration in early stages (...) of the microvasculature in hyperglycemic and hyperinsulinemic transgenic UCP1/DTA mice with brown fat deficiency, using a dorsal skin-fold chamber preparation and fluorescence microscopy. UCP1/DTA mice showed a dramatic decrease in vascular density due to a remarkable reduction of small vessels. Vascular permeability and leukocyte endothelial interactions (LEIs) significantly increased. The extent of vascular alteration correlated with the extent of metabolic dysfunction. Decreased tissue perfusion observed in UCP1

2003 Diabetes

960. Fulminant pulmonary calciphylaxis and metastatic calcification causing acute respiratory failure in a uremic patient. (PubMed)

Fulminant pulmonary calciphylaxis and metastatic calcification causing acute respiratory failure in a uremic patient. Calciphylaxis is a rare and life-threatening disorder characterized by small-vessel mural calcification with intimal proliferation, fibrosis, and thrombosis, resulting in tissue ischemic necrosis. Although it has been viewed as a systemic disease involving mainly the dermis, subcutaneous fat, or muscle, calciphylaxis of other organs rarely is reported. We describe the case

2006 American Journal of Kidney Diseases

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>